Danaher Is Poised For 'A Good Year In Bioprocessing': Analyst

Shares of Danaher Corp DHR tanked in early trading on Tuesday.

Stifel analyst Jacob Johnson says the company is poised for a gradual recovery in 2025. It could generate high-single-digit growth in the longer term, he predicts.

The Danaher Thesis: Johnson initiated coverage of Danaher with an Overweight rating and price target of $315.

Danaher completed a spinoff of its Environmental & Applied Solutions business in 2023. The company then emerged as a "pure-play LS tools company with operating companies in the Biotechnology, Life Sciences, and Diagnostics end-markets," Johnson added.

Check out other analyst stock ratings.

The EAS spinoff eliminated much of Danaher's industrial exposure. As a life sciences company, it remains focused on "higher growth, recurring revenue, and margins that warrant a higher multiple," the analyst stated.

"Like the broader space, DHR has faced headwinds over the last 12 to 18 months from bioprocessing destocking, the funding environment, China, and the roll-off from COVID," he wrote, while expressing optimism around "a gradual recovery in 2025 (with a good year in bioprocessing)."

DHR Price Action: Danaher shares declined by 1.05% to $275.07 at the time of publication on Tuesday.

Read More:

• Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: ‘It’s Up A Huge Amount’

Image: Shutterstock